Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Prescient Therapeutics Limited ( (AU:PTX) ) has shared an update.
Prescient Therapeutics Limited has announced the initiation of its first clinical site for the Phase 2a study of PTX-100, a potential treatment for Cutaneous T-Cell Lymphoma (CTCL). This milestone marks the beginning of a multi-site study across Australia, the USA, and Europe, evaluating the efficacy and safety of PTX-100 in approximately 40 patients. The study’s progress is significant for the company’s operations as it advances its first-in-class therapeutic candidate, potentially impacting its positioning in the oncology market and offering new hope for CTCL patients.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized medicine approaches for cancer treatment, including targeted and cellular therapies. Their product PTX-100 is a first-in-class compound targeting the cancer growth enzyme GGT-1, and they are also developing cell therapy platforms such as CellPryme-M, CellPryme-A, and OmniCAR.
YTD Price Performance: -12.00%
Average Trading Volume: 483,518
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$37.85M
Learn more about PTX stock on TipRanks’ Stock Analysis page.